Research
Hormonal
Resistin promotes inflammation and insulin resistance by binding to TLR4 and activating NF-kB, JNK, and p38 MAPK pathways in macrophages and hypothalamic cells.
Resistin, a protein elevated in obesity, contributes to inflammation and insulin resistance by activating specific immune pathways (TLR4/NF-kB). This highlights the complex interplay between fat tissue, immune cells, and metabolic health.
ModerateSupportsMEDIUM confidence
Mechanistically, resistin binds to TLR4 and activates NF-kB in human macrophages and mouse hypothalamic cells via the JNK and p38 MAPK pathways.
Why this rating
Based on in vitro and transgenic mouse studies.
Source
Adipokines, Hepatokines and Myokines: Focus on Their Role and Molecular Mechanisms in Adipose Tissue Inflammation
Yakun Ren et al. · Frontiers in Endocrinology · 2022
DOI 10.3389/fendo.2022.873699
narrative_reviewCited 214×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Elevated levels of pro-inflammatory adipokines (e.g., leptin, resistin, chemerin, FABP4) and reduced levels of anti-inflammatory adipokines (e.g., adiponectin) drive chronic low-grade inflammation in adipose tissue during obesity, contributing to insulin resistance and metabolic disorders.Moderate
- Leptin acts as a pro-inflammatory cytokine in adipose tissue by promoting macrophage infiltration and activation via JAK/STAT, MAPK, and PI3K pathways, contributing to local inflammation and lipid accumulation.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →